Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM5C | P41229 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22095994 | 0.90 | FAAH (0.61) | FAAHLMNAMCL1KMT2ATSHR | |
| SCHEMBL5909462 | 0.89 | FAAH (0.64) | FAAHMCL1KMT2ATSHRL3MBTL1 | |
| SCHEMBL19477898 | 0.88 | FAAH (0.72) | FAAHLMNAKMT2ACASP2HDAC3 | |
| SCHEMBL19731479 | 0.85 | FAAH (0.57) | FAAHKMT2ATSHRCASP2 | |
| SCHEMBL3660629 | 0.83 | LMNA (0.63) | LMNAMCL1POLBTSHRMMP2 | |
| SCHEMBL11173477 | 0.83 | FAAH (0.84) | FAAHKMT2ACASP2 | |
| SCHEMBL12931100 | 0.83 | FAAH (0.44) | FAAHLMNAMCL1KMT2APOLB | |
| SCHEMBL23735527 | 0.81 | ALDH1A1 (0.50) | FAAHLMNAMCL1KMT2APOLB | |
| SCHEMBL4404972 | 0.81 | MCL1 (0.46) | FAAHLMNAMCL1KMT2AMMP1 | |
| SCHEMBL21904602 | 0.81 | FAAH (0.42) | FAAHLMNAMCL1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | claimed |
| US-7465742-B2 | Heterocyclic compounds having anti-HBV activity | VRX HOLDCO LLC | 2008-12-16 | — | — | US | claimed |
| US-20060189643-A1 | Novel heterocyclic compounds having anti-HBV activity | BAUSCH+LOMB OPS B.V. (NL) | 2006-08-24 | — | — | US | claimed |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | ARDELYX, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-2384318-B1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-11-26 | — | — | US | disclosed |
| WO-2014169094-A2 | NHE3-BINDING COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014029983-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2014-02-27 | — | — | WO | disclosed |
| US-8304423-B2 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-02 | — | — | US | disclosed |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-01-05 | — | — | US | disclosed |
| US-7795298-B2 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. | 2010-09-14 | — | — | US | disclosed |
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | disclosed |
| US-7465742-B2 | Heterocyclic compounds having anti-HBV activity | VRX HOLDCO LLC | 2008-12-16 | — | — | US | disclosed |
| US-20070213315-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-13 | — | — | US | disclosed |
| US-20070093429-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20060189643-A1 | Novel heterocyclic compounds having anti-HBV activity | BAUSCH+LOMB OPS B.V. (NL) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093429-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | FAAH 4654/4885LMNA 404/4885MCL1 129/4885 |
| US-20070213315-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | FAAH 596/4885LMNA 4093/4885MCL1 4269/4885 |
| US-20150336892-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | FAAH 949/4885LMNA 3770/4885MCL1 4512/4885 |
| US-20120004226-A1 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | FAAH 596/4885LMNA 4093/4885MCL1 4269/4885 |
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | HCCS, HAVCR2, HMBS | FAAH 3842/4885LMNA 1552/4885MCL1 1197/4885 |
| US-20060189643-A1 | Novel heterocyclic compounds having anti-HBV activity | HCCS, HAVCR2, HMBS | FAAH 3842/4885LMNA 1552/4885MCL1 1197/4885 |
| US-20120196857-A9 | Modulators of Muscarinic Receptors | CHRM3, CHRM5, CHRM2 | FAAH 596/4885LMNA 4093/4885MCL1 4269/4885 |
| US-11858959-B2 | Glycyrrhetinic acid derivatives for use in treating hyperkalemia | HSD11B2, HSD11B1, NR3C2 | FAAH 3842/4885LMNA 3455/4885MCL1 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.